News: SIP Sigma Pharmaceuticals says FY reported EBIT expected to be broadly in line with last year

Feb 17 (Reuters) - Sigma Pharmaceuticals Ltd (SIP) :

• Advise that underlying ebit is expected to be just over $100 million for fy
• Fy reported ebit is however expected to be broadly in line with last year
• Sigma pharmaceuticals ltd - "remain comfortable with our existing guidance of at least 5% underlying ebit growth for 2017/18 financial year"
• Sigma pharmaceuticals - new guidance for full year compares with previous guidance of 10% underlying ebit growth